| Literature DB >> 34945618 |
Oscar Daniel Rangel-Huerta1, Lada Ivanova1, Silvio Uhlig1, Morten Sivertsvik2, Izumi Sone2, Estefanía Noriega Fernández2,3, Christiane Kruse Fæste1.
Abstract
Fresh baby spinach leaves are popular in salads and are sold as chilled and plastic-packed products. They are of high nutritional value but very perishable due to microbial contamination and enzymatic browning resulting from leaf senescence. Therefore, innovative food processing methods such as plasma-activated water (PAW) treatment are being explored regarding their applicability for ensuring food safety. PAW's impact on food quality and shelf-life extension has, however, not been investigated extensively in vegetables so far. In the present study, a comprehensive metabolomic analysis was performed to determine possible changes in the metabolite contents of spinach leaves stored in a refrigerated state for eight days. Liquid chromatography high-resolution mass spectrometry, followed by stringent biostatistics, was used to compare the metabolomes in control, tap-water-rinsed or PAW-rinsed samples. No significant differences were discernible between the treatment groups at the beginning or end of the storage period. The observed loss of nutrients and activation of catabolic pathways were characteristic of a transition into the senescent state. Nonetheless, the presence of several polyphenolic antioxidants and γ-linolenic acid in the PAW-treated leaves indicated a significant increase in stress resistance and health-promoting antioxidant capacity in the sample. Furthermore, the enhancement of carbohydrate-related metabolisms indicated a delay in the senescence development. These findings demonstrated the potential of PAW to benefit food quality and the shelf-life of fresh spinach leaves.Entities:
Keywords: food processing; food quality; metabolomics; plasma-activated water; senescence; spinach leaves
Year: 2021 PMID: 34945618 PMCID: PMC8702185 DOI: 10.3390/foods10123067
Source DB: PubMed Journal: Foods ISSN: 2304-8158
Figure 1Processing of fresh baby spinach leaves resulting in six treatment groups with n = 3 replicates per group. C: untreated control; C-S: untreated control stored for 8 days; TAP: tap-water-rinsed; TAP-S: tap-water-rinsed and stored for 8 days; PAW: plasma-activated-water-processed; PAW-S: plasma-activated-water-processed and stored for 8 days.
Concentration of nitrogen species, hydrogen peroxide, pH and ORP in PAW and TAP used in the spinach processing experiment.
| NO2 (mg/L) | NO3 (mg/L) | H2O2 (mg/L) | pH | ORP (mV) | |
|---|---|---|---|---|---|
| TAP | ND | ND | ND | 8.0 ± 0.1 | −45.3 ± 2.4 |
| PAW | 32.4 ± 5.6 | 462.3 ± 1.2 | 8.8 ± 0.4 | 2.3 ± 0.1 | 284.1 ± 11.5 |
ND: Non detected.
Figure 2PCA scores plot including QCs and all samples from LC-HRMS analysis. Quality control (QC); untreated control spinach (C: 1; C-S: 8); tap-water-rinsed spinach (TAP: 1; TAP-S: 8); plasma-activated-water-treated spinach (PAW: 1; PAW-S: 8).
Summary of multivariate models for quality assessment by PCA and differently processed spinach samples by OPLS-DA after analysis by LC-HRMS.
| Type | Model | Time Points | LV | R2X | R2Y | Q2 | |
|---|---|---|---|---|---|---|---|
| PCA | all samples | all | 3 | 0.691 | 0.405 | ||
| OPLS-DA | C vs. TAP vs. PAW | D1 | 1 + 0 + 0 | 0.257 | 0.412 | −0.0244 | NS |
| OPLS-DA | C-S vs. TAP-S vs. PAW-S | D8 | 1 + 0 + 0 | 0.210 | 0.376 | −0.0176 | NS |
| OPLS-DA | C vs. C-S | D1 vs. D8 | 1 + 0 + 0 | 0.618 | 0.961 | 0.933 |
|
| OPLS-DA | TAP vs. TAP-S | D1 vs. D8 | 1 + 0 + 0 | 0.764 | 0.993 | 0.967 |
|
| OPLS-DA | PAW vs. PAW-S | D1 vs. D8 | 1 + 0 + 0 | 0.790 | 0.993 | 0.971 |
|
PCA: principal component analysis; OPLS-DA: orthogonal partial least-squares discriminant analysis; LV: latent variable; R2X: total explained variance; R2Y: goodness of fit; Q2: predictive ability; p-value: ≤ 0.05 considered as significant (bold) (CV-ANOVA); NS: not significant.
Shared and unique relevant metabolites extracted from the comparison of C, TAP and PAW samples before (D1) and after 8 days of storage at 4 °C (D8).
| LC Mode | Ionisation Mode | Average RT | Average | Cluster Size a | Ion | Neutral Formula | Tentative Annotation (Spectral Match) | CANOPUS b Level | ClassyFire | Ann. Level c | D1 vs. D8 | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| C | C | TAP | TAP | PAW | PAW | |||||||||||
|
| ||||||||||||||||
| RPLC | pos | 1.97 | 166.0857 | 6 | [M + H]+ | C9H11NO2 |
| 7 | Phenylalanine and deriv. | 2 | 1.00 | 0.48 | 0.84 | 0.44 | 0.97 | 0.43 |
| HILIC | neg | 9.86 | 164.0714 | 3 | [M − H]− | C9H11NO2 |
| 7 | Phenylalanine and deriv. | 2 | 0.98 | 0.08 | 0.94 | 0.07 | 0.90 | 0.06 |
| RPLC | pos | 2.35 | 205.0968 | 16 | [M + H]+ | C11H12N2O2 | Tryptophan | 7 | α-amino acids | 2 | 0.98 | 0.24 | 0.92 | 0.27 | 0.97 | 0.27 |
| HILIC | neg | 12.27 | 175.0608 | 2 | [M − H]− | C7H12O5 | 2-Isopropylmalate | 6 | Meth. branched fatty acids | 2 | 0.99 | 0.21 | 0.84 | 0.20 | 0.92 | 0.21 |
| RPLC | neg | 2.66 | 175.0608 | 1 | [M − H]− | C7H12O5 | 2-Isopropylmalate | 6 | Meth. branched fatty acids | 2 | 0.99 | 0.12 | 0.66 | 0.11 | 0.81 | 0.13 |
| RPLC | pos | 1.20 | 182.0808 | 5 | [M + H]+ | C9H11NO3 | Tyrosine | 7 | Tyrosine and deriv. | 2 | 0.78 | 0.16 | 0.83 | 0.19 | 0.78 | 0.15 |
| HILIC | pos | 12.99 | 182.0808 | 3 | [M + H]+ | C9H11NO3 | Tyrosine | 7 | Tyrosine and deriv. | 2 | 0.95 | 0.13 | 0.95 | 0.12 | 0.74 | 0.09 |
| HILIC | neg | 15.64 | 117.0192 | 2 | [M − H]− | C4H6O4 | Succinate | Subclass | Dicarbox. acids and deriv. | 2 | 0.90 | 0.14 | 0.92 | 0.17 | 0.94 | 0.19 |
| HILIC | pos | 14.49 | 120.0652 | 2 | [M + H]+ | C4H9NO3 | L-(−)-Threonine | 7 | α-amino acids | 2 | 0.96 | 0.11 | 0.95 | 0.10 | 0.91 | 0.09 |
| HILIC | pos | 15.43 | 133.0605 | 1 | [M + H]+ | C4H8N2O3 | Asparagine | 7 | α-amino acids | 2 | 0.91 | 0.08 | 0.98 | 0.09 | 0.74 | 0.08 |
| HILIC | neg | 12.94 | 135.0305 | 2 | [M − H]− | C4H8O5 | Threonate | Subclass | β-hydroxy acids and deriv. | 2 | 0.94 | 0.08 | 0.96 | 0.10 | 0.94 | 0.10 |
| HILIC | pos | 3.88 | 679.2970 | 5 | [M + H]+ | C35H42N4O10 | Unknown | 6 | Oligopeptides | 3 | 0.89 | 0.08 | 0.77 | 0.08 | 0.74 | −0.05 |
| RPLC | pos | 1.14 | 245.0764 | 4 | [M + H]+ | C9H12N2O6 | Uridine | Class | Pyrimidine nucleosides | 2 | −0.83 | −0.05 | −0.89 | −0.07 | −0.89 | −0.08 |
| RPLC | pos | 2.80 | 374.1438 | 24 | [M + NH4]+ | C16H20O9 | 1-O-Feruloylglucose | 5 | Coumaric acids and deriv. | 2 | −0.98 | −0.12 | −0.92 | −0.10 | −0.69 | −0.05 |
| HILIC | pos | 14.73 | 148.0603 | 4 | [M + H]+ | C5H9NO4 | L-Glutamate | 7 | Glutamic acid and deriv. | 2 | −0.67 | −0.09 | −0.85 | −0.12 | −0.53 | −0.09 |
| RPLC | pos | 0.67 | 455.1137 | 1 | [M + Na]+ | C23H20N4O3S | Asperulosidic acid | 6 | Phenolic glycosides | 3 | −0.91 | −0.06 | −0.88 | −0.08 | −0.99 | −0.12 |
| RPLC | pos | 0.96 | 168.0652 | 1 | [M + H]+ | C8H9NO3 |
| 6 | Aryl-aldehydes | 2 | −0.92 | −0.08 | −0.90 | −0.09 | −0.96 | −0.10 |
| HILIC | pos | 7.39 | 168.0652 | 1 | [M + H]+ | C8H9NO3 |
| Subclass | Pyridine carboxaldehydes | 2 | −0.92 | −0.05 | −0.92 | −0.06 | −0.90 | −0.07 |
| HILIC | neg | 15.11 | 132.0300 | 1 | [M − H]− | C4H7NO4 | L-Aspartate | 8 | L-α-amino acids | 2 | −0.89 | −0.08 | −0.99 | −0.09 | −0.73 | −0.06 |
| RPLC | pos | 1.26 | 307.0830 | 1 | [M + H]+ | Unknown | Unknown | Subclass | 1-hydoxy-2-unsubstituted benzenoids | 4 | −0.89 | −0.08 | −0.97 | −0.09 | −0.87 | −0.09 |
| RPLC | neg | 0.71 | 133.0138 | 4 | [M − H]− | C4H6O5 | D-(+)-Malate | Subclass | β-hydroxy acids and deriv. | 2 | −0.90 | −0.14 | −0.55 | −0.07 | −0.64 | −0.06 |
| RPLC | pos | 0.55 | 146.1649 | 3 | [M + H]+ | C7H19N3 | Spermidine | 6 | Dialkylamines | 2 | −0.82 | −0.15 | −0.92 | −0.15 | −0.66 | −0.09 |
| HILIC | pos | 21.60 | 104.1067 | 2 | [M + H]+ | C5H14NO | Choline | 5 | Tetraalkylammonium salts | 2 | −0.62 | −0.23 | −0.73 | −0.18 | −0.97 | −0.24 |
| RPLC | pos | 1.56 | 268.1030 | 10 | [M + H]+ | C10H13N5O4 | Adenosine | Class | Purine nucleosides | 2 | −0.96 | −0.23 | −0.96 | −0.26 | −0.93 | −0.32 |
|
| ||||||||||||||||
|
| ||||||||||||||||
| RPLC | pos | 1.13 | 101.0232 | 4 | [M + H]+ | C4H4O3 | Succinic anhydride | Subclass | Dicarbox. acids and deriv. | 2 | 0.86 | 0.04 | 0.85 | 0.05 | 0.94 | 0.06 |
| HILIC | pos | 10.96 | 132.1016 | 4 | [M + H]+ | C6H13NO2 | DL-Norleucine | 6 | β-amino acids and deriv. | 3 | 0.31 | 0.04 | 0.59 | 0.10 | 0.54 | 0.06 |
| RPLC | pos | 1.89 | 199.1913 | 1 | [M + H]+ | C10H22N4 | Unknown | Subclass | Guanidines | 4 | −0.11 | −0.01 | −0.97 | −0.20 | −0.78 | −0.19 |
| HILIC | pos | 11.98 | 130.0861 | 1 | [M + H]+ | C6H11NO2 | Unknown | 6 | Amino acids | 3 | 0.39 | 0.03 | −0.58 | −0.05 | −0.62 | −0.11 |
| HILIC | pos | 25.21 | 123.0550 | 1 | [M + H]+ | C6H6N2O | Nicotinamide | 6 | Nicotinamides | 2 | −0.61 | −0.03 | −0.81 | −0.05 | −0.79 | −0.06 |
| RPLC | pos | 5.19 | 200.2009 | 1 | [M + H]+ | C12H25NO | Unknown | Subclass | Fatty amides | 3 | −0.92 | −0.04 | −0.95 | −0.05 | −0.98 | −0.05 |
|
| ||||||||||||||||
| RPLC | pos | 3.70 | 679.2974 | 3 | [M + H]+ | C35H42N4O10 | Unknown | 6 | α-amino acids and deriv. | 3 | 0.73 | 0.06 | 0.62 | 0.07 | 0.40 | 0.02 |
| RPLC | pos | 4.53 | 615.2780 | 5 | [M + H]+ | - | Unknown | Subclass | Billirubins | 4 | 0.87 | 0.05 | 0.70 | 0.05 | 0.89 | 0.04 |
| HILIC | pos | 10.38 | 132.1016 | 3 | [M + H]+ | C6H13NO2 | DL-Norleucine | 7 | α-amino acids | 3 | 0.59 | 0.09 | 0.34 | 0.08 | −0.21 | −0.04 |
| RPLC | pos | 5.46 | 368.4239 | 1 | [M + H]+ | Unknown | - | - | - | 4 | −0.92 | −0.06 | −0.70 | −0.05 | 0.04 | 0.00 |
| HILIC | neg | 16.60 | 133.0139 | 6 | [M − H]− | C4H6O5 | D-(+)-Malate | Subclass | β-hydroxy acids and deriv. | 3 | −0.56 | −0.11 | −0.72 | −0.13 | −0.36 | −0.06 |
| RPLC | pos | 5.14 | 279.1588 | 19 | [M + H]+ | C16H22O4 | Unknown | 5 | Benzoic acids | 4 | −0.84 | −0.20 | −0.70 | −0.17 | −0.34 | −0.08 |
| RPLC | pos | 0.70 | 360.1485 | 1 | [M + NH4]+ | C12H22O11 | - | 5 | Disaccharides | 3 | −0.70 | −0.05 | −0.82 | −0.05 | −0.81 | −0.04 |
|
| ||||||||||||||||
| HILIC | pos | 4.86 | 242.1283 | 1 | [M + H]+ | C14H15N3O | Unknown | Subclass | Cinnamic acid amides | 3 | 0.57 | 0.05 | 0.42 | 0.02 | 0.75 | 0.08 |
| HILIC | pos | 18.01 | 156.0765 | 1 | [M + H]+ | C6H9N3O2 | Histidine | 7 | Histidine and deriv. | 3 | 0.87 | 0.06 | 0.68 | 0.04 | 0.86 | 0.07 |
| HILIC | neg | 18.59 | 191.0193 | 2 | [M − H]− | C6H8O7 | Citrate | Subclass | Tricarboxylic acids and deriv. | 3 | −0.90 | −0.14 | −0.35 | −0.04 | −0.50 | −0.08 |
| HILIC | neg | 18.10 | 173.0091 | 1 | [M − H]− | C6H6O6 | Aconitate | Subclass | Tricarboxylic acids and deriv. | 3 | −0.65 | −0.05 | −0.62 | −0.04 | −0.63 | −0.05 |
|
| ||||||||||||||||
|
| ||||||||||||||||
| RPLC | pos | 1.48 | 132.1016 | 4 | [M + H]+ | C6H13NO2 | DL-Norleucine | 7 | α-amino acids | 3 | −0.82 | −0.29 | −0.19 | −0.09 | −0.61 | −0.21 |
|
| ||||||||||||||||
| HILIC | pos | 9.26 | 114.0660 | 1 | [M + H]+ | C4H7N3O | Creatinine | 6 | α-amino acids and deriv. | 2 | 0.45 | 0.00 | −0.51 | −0.05 | −0.40 | −0.01 |
| RPLC | pos | 2.52 | 155.1541 | 1 | [M + H]+ | Unknown | - | - | - | 4 | −0.16 | 0.00 | −0.69 | −0.18 | −0.30 | 0.00 |
| RPLC | pos | 3.78 | 171.1489 | 1 | [M + H]+ | C9H18N2O | - | Class | Organic carbonic acids and deriv. | 3 | −0.80 | −0.01 | −0.61 | −0.14 | −0.67 | −0.01 |
| HILIC | pos | 10.76 | 118.0859 | 1 | [M + H]+ | C5H11NO2 | Glycine Betaine | - | - | 4 | −0.43 | −0.08 | −0.67 | −0.17 | 0.05 | 0.02 |
|
| ||||||||||||||||
| RPLC | pos | 3.12 | 242.1284 | 1 | [M + H]+ | C14H15N3O | - | Subclass | Cinnamic acid amides | 3 | 0.40 | 0.05 | 0.02 | 0.00 | 0.67 | 0.11 |
| HILIC | neg | 14.20 | 165.0192 | 1 | [M − H − H2O]− | C8H8O5 | - | Subclass | α-hydroxy acids and deriv. | 3 | 0.87 | 0.04 | 0.01 | 0.00 | 0.98 | 0.06 |
| RPLC | neg | 5.33 | 447.2512 | 1 | [M − H]− | Unknown | - | - | - | 4 | −0.48 | −0.01 | −0.71 | −0.03 | −0.89 | −0.06 |
| HILIC | neg | 3.46 | 277.2166 | 3 | [M − H]− | C18H30O2 | γ-Linolenic acid | Subclass | Glycerophosphocholine | 3 | 0.04 | 0.00 | 0.30 | 0.04 | −0.88 | −0.10 |
| HILIC | pos | 11.60 | 244.0924 | 1 | [M + H]+ | C9H13N3O5 | Cytidine | Class | Pyrimidine nucleosides | 2 | −0.73 | −0.03 | −0.93 | −0.04 | −0.85 | −0.05 |
| HILIC | pos | 8.98 | 136.0616 | 1 | [M + H]+ | C5H5N5 | Adenine | 5 | 6-aminopurines | 2 | −0.70 | −0.03 | −0.66 | −0.04 | −0.58 | −0.05 |
| RPLC | pos | 5.62 | 496.3395 | 2 | [M + H]+ | C24H50NO7P | Lysophosphatidylcholine (16:0) | 5 | Lysophosphatidylcholines | 2 | −0.55 | −0.04 | −0.02 | 0.00 | −0.77 | −0.07 |
| HILIC | neg | 4.68 | 519.0775 | 2 | [M − H]− | C23H20O14 | 5,3’,4’,-Trihydroxy-3-methoxy-6:7-methylenedioxyflavone 4’-βD-glucuronide | 7 | Flavonoid-7-O-glucuronides | 3 | 0.42 | 0.03 | −0.15 | −0.01 | −0.63 | −0.07 |
|
| ||||||||||||||||
| RPLC | pos | 1.79 | 168.1014 | 3 | [M + H]+ | C9H13NO2 |
| Subclass | Phenethyl amines | 2 | −0.86 | −0.08 | −0.86 | −0.07 | 0.71 | 0.07 |
| HILIC | pos | 15.03 | 147.0763 | 3 | [M + H]+ | C5H10N2O3 | Glutamine | 7 | α-amino acids | 2 | −0.55 | −0.09 | 0.19 | 0.05 | 0.37 | 0.06 |
| HILIC | pos | 12.22 | 118.0859 | 1 | [M + H]+ | C5H11NO2 | Valine | 7 | α-amino acids | 2 | 0.50 | 0.05 | 0.19 | 0.03 | −0.78 | −0.07 |
| RPLC | pos | 0.63 | 175.1184 | 1 | [M + H]+ | C6H14N4O2 | Arginine | 8 | L-α-amino acids | 2 | 0.78 | 0.11 | 0.32 | 0.04 | −0.50 | −0.07 |
| RPLC | pos | 5.71 | 282.2782 | 1 | [M + H]+ | C18H35NO | - | Subclass | Fatty amides | 2 | −0.42 | −0.03 | 0.45 | 0.07 | −0.61 | −0.05 |
| RPLC | neg | 3.12 | 279.0504 | 12 | [M − H]− | C13H12O7 | 2-(p-coumaroyl)malate | 6 | Coumaric acid esters | 3 | −0.85 | −0.07 | −0.74 | −0.05 | 0.58 | 0.04 |
| RPLC | pos | 1.38 | 138.0913 | 2 | [M + H]+ | C8H11NO | Tyramine | 5 | Aralkylamines | 2 | −0.95 | −0.07 | −0.69 | −0.05 | 0.66 | 0.03 |
The metabolites in each category are sorted according to probability (sum of p(corr) of C, TAP and PAW). RPLC: reverse-phase liquid chromatography; HILIC: hydrophilic interaction liquid chromatography; pos: positive; neg: negative; RT: retention time. The MS/MS spectra of underlined metabolites are also shown in Figure 3. a Cluster size: clusters can contain differently charged ion adducts of a metabolite (Supplementary Table S2a,b). The metabolic feature with the most intense ion is shown in Table 3. b CANOPUS level: CANOPUS provided the possibility of assigning compound classes to otherwise unidentified features for which no spectral reference data were available. The classification considers the structure-based chemical taxonomy (ChemOnt) built using ClassyFire that uses only chemical structures and structural features for the automatic assignment of all known chemical compounds to a taxonomy consisting of >4800 different categories. ChemOnt is organised as a tree, where the Kingdom is either Organic compounds or Inorganic compounds. Superclasses such as Lipids and Lipid-like Molecules, and Benzenoids are categories in a Kingdom. Pyrimidine nucleosides constitute a class, whereas guanidine is an example of a subclass. There can be up to 11 levels in the ontology. c Annotation level of identification: level 1—unambiguously identified metabolite; level 2—putatively identified metabolite; level 3—tentatively characterised metabolite class; level 4—unidentified or unclassified metabolite, but differentiable. d The direction of the change is indicated by the plus/minus sign in front of the number.
Figure 3Measured MS/MS spectra (up, in black) matched to the respective reference spectra from the MS-DIAL curated library (down, in red) for (a) phenylalanine (MS/MS of [M − H]−), (b) pyridoxal (MS/MS of [M + H]+) and (c) methoxytyramine (MS/MS of [M + H]+).
Figure 4KEGG pathway association of metabolites changed during storage (D1 vs. D8) in differently processed spinach leaves (C, TAP or PAW) and identified by HILIC- or RPLC-HRMS. The MS Peaks to Pathway analysis by mummichog shows significantly affected pathways (see Supplementary Table S3) as red dots, whose sizes are dependent on their connected p-values (see Section 2.7.2). The five most-changed pathways are named for each sample group.
Comparison of KEGGa pathways allocated to metabolite changes observed during storage (D1 to D8) in differently processed spinach leaves.
| C | TAP | PAW |
|---|---|---|
| Alanine, aspartate and glutamate metabolism | Alanine, aspartate and glutamate metabolism | |
| Aminoacyl-tRNA biosynthesis | Aminoacyl-tRNA biosynthesis | |
|
| ||
|
| ||
|
| ||
|
| ||
| Cysteine and methionine metabolism | Cysteine and methionine metabolism | |
|
| ||
|
| ||
|
| ||
|
| ||
|
|
a KEGG pathways, s. Supplementary Table S3. Uniquely changed metabolite pathways are underlined in the respective treatment groups.